Table II.
Characteristic | Non-comminuted fracture (n = 94) | Comminuted fracture (n = 28) | p-value |
---|---|---|---|
Median age, yrs (IQR) | 72 (61 to 78) | 72.5 (67 to 79) | 0.439* |
Median BMI, kg/m2 (IQR) | 22.3 (19.6 to 24.8) | 21.9 (20.2 to 23.8) | 0.801* |
Current smoking status, n (%) | 2 (2) | 0 | 0.421† |
Steroid intake, n | 0 | 0 | |
Diabetes mellitus, n (%) | 9 (9.5) | 2 (7.1) | 0.693† |
Median eGFR, ml/min (IQR) | 68.5 (59.2 to 79) | 71.2 (58.2 to 78.9) | 0.801* |
Osteoporosis treatment, n (%) | 10 (10.6%) | 5 (17.8%) | 0.786† |
Bisphosphonate | 9 | 3 | |
Denosumab | 1 | 1 | |
Others | 0 | 1 | |
Median BMD T-score (IQR) | |||
Lumbar spine | -2.0 (-2.9 to -0.8) | -2.0 (-2.7 to -1.2) | 0.859* |
Femoral neck | -2.2 (-3.1 to -1.6) | -2.6 (-3.0 to -1.7) | 0.491* |
Forearm | -2.7 (-3.8 to -1.0) | -2.2 (-3.4 to -1.5) | 0.911* |
Median P1NP, μg/l (IQR) | 58.0 (43.6 to 74.5) | 56.8 (42.6 to 68.7) | 0.712* |
Median TRACP-5b, mU/dl (IQR) | 413 (319 to 522) | 416 (319 to 496) | 0.801* |
Median intact-PTH level, pg/m (IQR) | 39.0 (31.0 to 50.0) | 44.2 (36.9 to 56.0) | 0.072* |
Median ucOC level, ng/ml (IQR) | 4.9 (3.4 to 7.5) | 6.0 (3.8 to 9.1) | 0.244* |
Mann-Whitney U test.
Chi-squared test.
BMD, bone mineral density; eGFR, estimated glomerular filtration ratio; IQR, interquartile range; P1NP, total type 1 procollagen N-terminal propeptide; PTH, parathyroid hormone; TRACP-5b, tartrate-resistant acid phosphatase 5b; ucOC, undercarboxylated osteocalcin.